Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.

Amikacin / pharmacology Antitubercular Agents / pharmacology Extensively Drug-Resistant Tuberculosis / drug therapy Fluoroquinolones / pharmacology Humans Microbial Sensitivity Tests Mycobacterium tuberculosis Ofloxacin South Africa / epidemiology Tuberculosis, Multidrug-Resistant / drug therapy

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 06 2022
Historique:
received: 30 11 2021
accepted: 09 06 2022
entrez: 27 6 2022
pubmed: 28 6 2022
medline: 30 6 2022
Statut: epublish

Résumé

Tuberculosis (TB) remains a leading infectious disease killer globally. Treatment outcomes are especially poor among people with extensively drug-resistant (XDR) TB, until recently defined as rifampicin-resistant (RR) TB with resistance to an aminoglycoside (amikacin) and a fluoroquinolone (ofloxacin). We used laboratory TB test results from Western Cape province, South Africa between 2012 and 2015 to identify XDR-TB and pre-XDR-TB (RR-TB with resistance to one second-line drug) spatial hotspots. We mapped the percentage and count of individuals with RR-TB that had XDR-TB and pre-XDR-TB across the province and in Cape Town, as well as amikacin-resistant and ofloxacin-resistant TB. We found the percentage of pre-XDR-TB and the count of XDR-TB/pre-XDR-TB highly heterogeneous with geographic hotspots within RR-TB high burden areas, and found hotspots in both percentage and count of amikacin-resistant and ofloxacin-resistant TB. The spatial distribution of percentage ofloxacin-resistant TB hotspots was similar to XDR-TB hotspots, suggesting that fluoroquinolone-resistace is often the first step to additional resistance. Our work shows that interventions used to reduce XDR-TB incidence may need to be targeted within spatial locations of RR-TB, and further research is required to understand underlying drivers of XDR-TB transmission in these locations.

Identifiants

DOI: 10.1038/s41598-022-14581-4 PMID: 35760977 PMC: PMC9237070
pubmed: 35760977
doi: 10.1038/s41598-022-14581-4
pii: 10.1038/s41598-022-14581-4
pmc: PMC9237070
doi:

Substances chimiques

Antitubercular Agents 0
Fluoroquinolones 0
Amikacin 84319SGC3C
Ofloxacin A4P49JAZ9H

Banques de données

figshare
['10.6084/m9.figshare.17102636.v1']

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

10844

Subventions

Organisme : NIH HHS
ID : K01AI102944
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI147316
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM074905
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152126
Pays : United States
Organisme : NIH HHS
ID : K01TW009213
Pays : United States
Organisme : NIH HHS
ID : P30AI042853
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI119037
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI144335
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI102944
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Lancet. 2006 Nov 4;368(9547):1575-80
pubmed: 17084757
J Infect Dis. 2016 Jan 15;213(2):287-94
pubmed: 26175455
J Pak Med Assoc. 2017 Feb;67(2):270-274
pubmed: 28138184
PLoS One. 2017 Oct 13;12(10):e0181797
pubmed: 29028800
PLoS One. 2017 Feb 9;12(2):e0171800
pubmed: 28182726
Int J Tuberc Lung Dis. 2019 Jun 1;23(6):720-727
pubmed: 31315705
Int J Tuberc Lung Dis. 2013 Jan;17(1):100-6
pubmed: 23232009
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):287-293
pubmed: 29471906
Eur Respir J. 2013 Nov;42(5):1291-301
pubmed: 23100496
Int J Infect Dis. 2010 Oct;14(10):e828-37
pubmed: 20570541
N Engl J Med. 2012 Sep 6;367(10):931-6
pubmed: 22931261
Epidemiol Infect. 2011 Nov;139(11):1784-93
pubmed: 21205434
Clin Infect Dis. 2020 May 6;70(10):2224-2227
pubmed: 31538648
PLoS One. 2019 Oct 17;14(10):e0223308
pubmed: 31622366
Int J Tuberc Lung Dis. 2015 Feb;19(2):216-22
pubmed: 25574922
N Engl J Med. 2017 Jan 19;376(3):243-253
pubmed: 28099825
PLoS One. 2011;6(5):e17513
pubmed: 21655324
Emerg Infect Dis. 2021;27(3):728-739
pubmed: 33622466
Euro Surveill. 2014 Mar 20;19(11):
pubmed: 24679722
PLoS Med. 2018 Aug 21;15(8):e1002638
pubmed: 30130377
Trop Med Int Health. 2015 Oct;20(10):1337-45
pubmed: 25975868
Lancet Infect Dis. 2018 Jul;18(7):779-787
pubmed: 29685458
PLoS One. 2018 Apr 18;13(4):e0196003
pubmed: 29668748
Sci Rep. 2020 Oct 6;10(1):16646
pubmed: 33024245

Auteurs

Karla Therese L Sy (KTL)

Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.

Sarah V Leavitt (SV)

Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.

Margaretha de Vos (M)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Tania Dolby (T)

National Health Laboratory Service, Cape Town, South Africa.

Jacob Bor (J)

Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.

C Robert Horsburgh (CR)

Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Department of Global Health, Boston University School of Public Health, Boston, MA, USA.
Section of Infectious Diseases, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA.

Robin M Warren (RM)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Elizabeth M Streicher (EM)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Helen E Jenkins (HE)

Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.

Karen R Jacobson (KR)

Section of Infectious Diseases, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA. kjacobso@bu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Kanamycine › Amikacine › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Tuberculose multirésistante › Tuberculose ultrarésistante aux médicaments › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Fluoroquinolones › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Fluoroquinolones › Ofloxacine › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Afrique australe › République d'Afrique du Sud › Spatial heterogeneity of extensively drug...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Tuberculose multirésistante › Spatial heterogeneity of extensively drug...